William W.L. Wong
Has grant
Associate Professor
Research Interests
Explore related searches
Contact this professor
About
William W.L. Wong is an Associate Professor at the University of Waterloo, Canada. His research areas primarily focus on healthcare economics, particularly related to hepatitis B and C, including their prevalence, treatment costs, and patient outcomes. His recent publications examine the effectiveness and impact of antiviral therapies and public health strategies in Canadian healthcare settings.
Recent Grants
Grant: Close
Improvements in quality of life, health utility, cost, and return to work for lymphoma patients after chimeric antigen receptor T- cells therapy in a real-world setting
Open Date: 2022-03-01
Close Date: 2023-02-28
Grant: Close
Estimating chronic hepatitis B prevalence and the undiagnosed proportion in Canada using health administrative data
Open Date: 2021-11-01
Close Date: 2022-10-31
Grant: Close
Understanding the treatment benefits of chimeric antigen receptor T-cells for lymphoma: quality of life, health utility, cost, and return to work
Open Date: 2021-03-01
Close Date: 2022-02-28
Grant: Close
The Response of Provincial Health Systems to COVID-19: Service Provision and Costs Across Health Sectors, First Nations and other populations
Open Date: 2020-06-01
Close Date: 2020-09-30
Grant: Close
Real-world effectiveness and cost-effectiveness of novel hepatitis C treatments
Open Date: 2020-04-01
Close Date: 2022-03-31
Articles (15)
Hepatitis C Attributable Healthcare Costs and Mortality among Immigrants: A Population-Based Matched Cohort Study
Background. Data on the economic burden of chronic hepatitis C (CHC) among immigrants are limited. Our objective was to estimate the CHC-attributable mortality and healthcare costs among immigrants in Ontario, Canada. Methods. We conducted a population-based matched cohort study among immigrants diagnosed with CHC between May 31, 2003, and December 31, 2018, using linked health administrative data. Immigrants with CHC (exposed) were matched 1 : 1 to immigrants without CHC (unexposed) using a combination of hard (index date, sex, and age) and propensity-score matching. Net costs (2020 Canadian dollars) collected from the healthcare payer perspective were calculated using a phase-of-care approach and used to estimate long-term costs adjusted for survival. Results. We matched 5,575 exposed individuals with unexposed controls, achieving a balanced match. The mean age was 47 years, and 52% was male. On average, 10.5% of exposed and 3.5% of unexposed individuals died 15 years postindex (relative risk = 2.9; 95% confidence interval (CI): 2.6–3.5). The net 30-day costs per person were $88 (95% CI: 55 to 122) for the prediagnosis, $324 (95% CI: 291 to 356) for the initial phase, $1,016 (95% CI: 900 to 1,132) for the late phase, and $975 (95% CI: −25 to 1,974) for the terminal phase. The mean net healthcare cost adjusted for survival at 15 years was $90,448. Conclusions. Compared to unexposed immigrants, immigrants infected with CHC have higher mortality rates and greater healthcare costs. These findings will support the planning of HCV elimination efforts among key risk groups in the province.
Year:
2024
Collaborators (6)
Mhd. Wasem Alsabbagh
Associate Professor
University of Waterloo Faculty of Science
Jennifer D Walker
Associate Professor
McMaster University
Andrew P Costa
McMaster University
Mina Tadrous
University of Toronto
Naveed Janjua
Clinical Professor
The University of British Columbia
Beate Sander
University Health Network

How do I reach out?
Sign in for free to see their profile details and contact information.